International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2025
Classic pathway persistent complement activation is associated with specific symptoms in individuals with post-COVID-19 condition: A case-control study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Fernández-de-Las-Peñas César, Ruiz-Ruigómez Maria, Esparcia-Pinedo Laura, Colom-Fernández Beatriz, Cava-Valenciano Fernando, Torres-Macho Juan, Arrieta-Ortubay Estibaliz, Akasbi-Moltalvo Míriam, Lumbreras-Bermejo Carlos, Arendt-Nielsen Lars, Franco-Moreno Anabel
Аннотация
OBJECTIVES: The complement system is a crucial part of the immune system. The role of complement activation in post-COVID-19 condition is still not conclusive. We present a case-control study investigating long-lasting complement hyperactivation in COVID-19 survivors with/without post-COVID-19 condition.
METHODS: A case-control (2:1 design) study was performed. Concentration levels of four proteins from classic complement pathway (C3, C4, C5, C7) and total hemolytic complement (CH50) activity were obtained from blood samples in group of survivors with post-COVID-19 condition and in a comparison group of survivors without post-COVID-19 condition, matched by age, sex, and vaccination status. Post-COVID-19 condition was defined when individuals self-reported at least one of these post-COVID-19 symptoms: fatigue, arthralgia, myalgia, memory problems, new-onset headache, or palpitations.
RESULTS: A total of 57 (56.1% women, age: 46.5 years, SD: 9.0 years) survivors with post-COVID-19 condition and 27 (55.5% women, age: 46.5 years, SD: 11.5 years) survivors without post-COVID-19 condition were evaluated 1.7 (SD 1.2) and 2.0 (SD 1.7) years after SARS-CoV-2 infection, respectively. Overall, the results did not reveal differences in complement protein levels and CH50 activity between survivors with or without post-COVID-19 condition. Patients reporting post-COVID fatigue exhibited lower C3 levels (P = 0.025) than those without post-COVID fatigue, whereas survivors with post-COVID dyspnea reported lower levels of C3 (P = 0.001), C5 (P = 0.015), and C7 (P = 0.030) proteins than those without post-COVID dyspnea.
CONCLUSIONS: This explorative case-control study did not observe overall complement activation from classic pathway in survivors with post-COVID-19 condition up to 2 years after. Some complement proteins were elevated in individuals with specific post-COVID symptoms, such as fatigue or dyspnea.
METHODS: A case-control (2:1 design) study was performed. Concentration levels of four proteins from classic complement pathway (C3, C4, C5, C7) and total hemolytic complement (CH50) activity were obtained from blood samples in group of survivors with post-COVID-19 condition and in a comparison group of survivors without post-COVID-19 condition, matched by age, sex, and vaccination status. Post-COVID-19 condition was defined when individuals self-reported at least one of these post-COVID-19 symptoms: fatigue, arthralgia, myalgia, memory problems, new-onset headache, or palpitations.
RESULTS: A total of 57 (56.1% women, age: 46.5 years, SD: 9.0 years) survivors with post-COVID-19 condition and 27 (55.5% women, age: 46.5 years, SD: 11.5 years) survivors without post-COVID-19 condition were evaluated 1.7 (SD 1.2) and 2.0 (SD 1.7) years after SARS-CoV-2 infection, respectively. Overall, the results did not reveal differences in complement protein levels and CH50 activity between survivors with or without post-COVID-19 condition. Patients reporting post-COVID fatigue exhibited lower C3 levels (P = 0.025) than those without post-COVID fatigue, whereas survivors with post-COVID dyspnea reported lower levels of C3 (P = 0.001), C5 (P = 0.015), and C7 (P = 0.030) proteins than those without post-COVID dyspnea.
CONCLUSIONS: This explorative case-control study did not observe overall complement activation from classic pathway in survivors with post-COVID-19 condition up to 2 years after. Some complement proteins were elevated in individuals with specific post-COVID symptoms, such as fatigue or dyspnea.